文献速递乳腺癌

大规模免疫逃逸:理解乳腺癌不同亚型中分歧的免疫反应

The Great Immune Escape: Understanding the Divergent Immune Response in Breast Cancer Subtypes.
PubMed 文献 · Cancer Discov · 2023-01-01

乳腺癌包含多种组织学(主要为导管和小叶)和分子亚型,临床表现、病程、治疗选择和结局各异。免疫治疗已革新部分实体瘤治疗,但在乳腺癌中前景有限。本综述总结乳腺癌各亚型中肿瘤与免疫细胞复杂相互作用在细胞和微环境层面的最新进展,旨在为针对各亚型特定特征定制未来免疫治疗药物提供视角。

要点

  • 乳腺癌包含多种组织学和分子亚型,临床特征与结局各异
  • 免疫治疗在部分实体瘤中已革新治疗,但在乳腺癌中前景有限
  • 目前超过200项免疫治疗临床试验主要限于三阴性和HER2+亚型且聚焦T细胞

核心结论

  • 需识别并突出每种乳腺癌亚型独特的挑战与机遇,以推动利用免疫系统的下一代治疗。

研究设计与样本

  • 综述,总结乳腺癌各亚型中肿瘤与免疫细胞相互作用在细胞和微环境层面的最新进展。

主要发现

  • 乳腺癌包含多种组织学(主要为导管和小叶)和分子亚型,临床表现、病程、治疗选择和结局各异。
  • 免疫治疗已革新部分实体瘤治疗,但在乳腺癌中前景有限。
  • 目前超过200项正在进行的免疫治疗临床试验主要限于三阴性和HER2+亚型,且主要聚焦T细胞。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Breast cancer, the most common type of cancer affecting women, encompasses a collection of histologic (mainly ductal and lobular) and molecular subtypes exhibiting diverse clinical presentation, disease trajectories, treatment options, and outcomes. Immunotherapy has revolutionized treatment for some solid tumors but has shown limited promise for breast cancers. In this review, we summarize recent advances in our understanding of the complex interactions between tumor and immune cells in subtypes of breast cancer at the cellular and microenvironmental levels. We aim to provide a perspective on opportunities for future immunotherapy agents tailored to specific features of each subtype of breast cancer. SIGNIFICANCE: Although there are currently over 200 ongoing clinical trials testing immunotherapeutics, such as immune-checkpoint blockade agents, these are largely restricted to the triple-negative and HER2+ subtypes and primarily focus on T cells. With the rapid expansion of new in vitro, in vivo, and clinical data, it is critical to identify and highlight the challenges and opportunities unique for each breast cancer subtype to drive the next generation of treatments that harness the immune system.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Onkar SS, Carleton NM, Lucas PC, et al. The Great Immune Escape: Understanding the Divergent Immune Response in Breast Cancer Subtypes. Cancer Discov. 2023. PMID: 36620880. doi:10.1158/2159-8290.CD-22-0475

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。